The cells of a subset of myeloproliferative neoplasms (MPNs), slow-growing blood cancers, have frameshift mutations in their calreticulin (CALR) gene that are associated with the disease. The tail end of this gene's mutated ...
Sep 20, 2022
0
5
Three genetic alterations associated with a rare seizure and a movement disorder primarily found in children were successfully mirrored in mice and their symptoms treated, in a new study from a University of Maryland School ...
Aug 15, 2022
0
19
An analysis of SARS-CoV-2 variants sequenced in a scientific database GISAID has found some mutant strains of the virus could resist the COVID-19 medication Paxlovid.
Jul 5, 2022
0
19
Blocking the mutant protein with an antibody didn't stop the strange, abnormal bone growths in mice. But the knowledge gained could steer scientists toward more promising approaches, report researchers from UConn and Alexion ...
Jun 17, 2022
0
90
A team of researchers led by Dr. Sandra Castillo and Dr. Mariona Graupera, from the Josep Carreras Leukaemia Research Institute and CIBERONC, have found the AKT inhibitor miransertib could be a new, effective molecular treatment ...
Jun 14, 2022
0
19
In a novel experiment, a woman with advanced pancreatic cancer saw her tumors dramatically shrink after researchers in Oregon turbocharged her own immune cells, highlighting a possible new way to someday treat a variety of ...
Jun 2, 2022
0
307
Mutant mice are providing scientists with a new neurobiological framework to understand the brain changes observed in distractible humans who carry a common gene variant whose frequency has been associated with Attention ...
Apr 7, 2022
0
321
Timing is key when treating developmental disorders. Blocking an overactive signaling pathway during the first five weeks of life prevents autism symptoms from ever developing in mice, according to new research published ...
Feb 21, 2022
0
0
Researchers at the University of Toronto have identified hundreds of new proteins that could play a role in cystic fibrosis, and which may shed light on why some patients respond better than others to current therapies.
Feb 14, 2022
0
7
As a 10-year journey comes to fruition, Medical University of South Carolina (MUSC) Hollings Cancer Center researcher John O'Bryan, Ph.D., and colleagues have demonstrated a new therapeutic way to block a protein that is ...
Feb 8, 2022
0
64
